by Jasmine Hagan – RegMedNet
The UK is set to be the second country to trial a pioneering stem cell robot to improve the manufacture of safe and cost-effective cell-based therapeutics.
Manufacturing challenges have limited the availability of stem cell-based therapeutics and now, to overcome these challenges, the Medicines and Healthcare products Regulatory Agency (MHRA; London, UK) have announced that a stem cell propagation robot will be trialed by the MHRA UK Stem Cell Bank over a 12-month period.
The CellQualia™ Intelligent Cell Processing System, which was developed in Japan, automates the culturing of cells in real-time and stabilizes the process by utilizing intelligent process analytical technology. It is capable of automated sowing, process monitoring, medium change, passaging and harvesting. The technology also utilizes a fully closed system to reduce the risk of contamination, ensuring that the cells are of a high quality.